Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Harvard Bioscience, Inc. (HBIO) Names Jeffrey A. Duchemin To The Additional Roles Of President And Director

|Includes: Harvard Bioscience, Inc. (HBIO)

Global developer, manufacturer, and marketer of a broad range of tools to advance life science research and regenerative medicine, Harvard Bioscience announced that its Chief Executive Officer, Jeffrey A. Duchemin, has been appointed to the additional positions of President and Director, effective immediately. He is set to replace David Green, who became the President of Harvard Apparatus Regenerative Technology, Inc. (HART), a spin off from HBIO, on November 1, 2013. Green will remain on the Board of Directors of Harvard Bioscience.

David Green stated, "Guiding Harvard Bioscience successfully into its future requires a leader with profound understanding of the life sciences industry, a specific grasp of its customer base, and the know-how to expand the Company's growth internationally. In the few months since he took the helm of HBIO as Chief Executive Officer, Jeff has proven himself eminently qualified for this position, and I look forward to watching him continue to grow the Company."

Jeffrey A. Duchemin commented, "As President and Chief Executive Officer of Harvard Bioscience, I intend to implement a comprehensive set of goals that includes overseeing the organic growth of the Company, embarking on a program of geographic expansion and managing strategic growth via acquisitions. I have already begun to assemble a key team of managers to assist me in this goal, and I look forward to sharing key milestones with shareholders as we move ahead. I would also like to thank David Green for his years of dedication to Harvard Bioscience and for contributing to its success."

Prior to joining Harvard Bioscience as the Chief Executive Officer this August, Duchemin spent 16 years with Becton Dickinson (BD) in progressive sales, executive leadership and marketing positions across the company's three business segments: BD Biosciences, BD Medical Systems, and BD Diagnostic Systems. In October of 2012, BD Biosciences, Discovery Labware was acquired by Corning Life Sciences. Duchemin was previously a Global Business Director for Corning Life Sciences until leaving to take a position with Harvard Bioscience. A results driven leader, the depth of his expertise spans across a broad range of life science research and medical device products, resulting in impressive growth on an international basis. Duchemin holds an M.B.A. from Southern New Hampshire University and a Bachelor of Science degree from the University of Massachusetts Dartmouth in accounting.

On an additional note, Harvard Bioscience announced that the position of Chief Operating Officer is to be eliminated as of November 30, 2013. Duchemin is set to take on the responsibilities of that position.

To learn more, please visit

MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit